Email updates

Keep up to date with the latest news and content from Proteome Science and BioMed Central.

Open Access Research

Patients with ovarian carcinoma excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin

Siti S Abdullah-Soheimi1, Boon-Kiong Lim2, Onn H Hashim34 and Adawiyah S Shuib14*

Author Affiliations

1 Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia

2 Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

3 Department of Molecular Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

4 University of Malaya Centre for Proteomics Research, University of Malaya, Kuala Lumpur, Malaysia

For all author emails, please log on.

Proteome Science 2010, 8:58  doi:10.1186/1477-5956-8-58

Published: 17 November 2010

Abstract

Background

Diagnosis of ovarian carcinoma is in urgent need for new complementary biomarkers for early stage detection. Proteins that are aberrantly excreted in the urine of cancer patients are excellent biomarker candidates for development of new noninvasive protocol for early diagnosis and screening purposes. In the present study, urine samples from patients with ovarian carcinoma were analysed by two-dimensional gel electrophoresis and the profiles generated were compared to those similarly obtained from age-matched cancer negative women.

Results

Significant reduced levels of CD59, kininogen-1 and a 39 kDa fragment of inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4), and enhanced excretion of a 19 kDa fragment of albumin, were detected in the urine of patients with ovarian carcinoma compared to the control subjects. The different altered levels of the proteins were confirmed by Western blotting using antisera and a lectin that bind to the respective proteins.

Conclusion

CD59, kininogen-1 and fragments of ITIH4 and albumin may be used as complementary biomarkers in the development of new noninvasive protocols for diagnosis and screening of ovarian carcinoma.